Quality-of-life assessment in French patients with metastatic melanoma in real life.
Fiche publication
Date publication
octobre 2019
Journal
Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Dr DALAC Sophie, Dr GRANEL-BROCARD Florence
Tous les auteurs :
Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I
Lien Pubmed
Résumé
Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an assessment of quality of life (QoL) during the whole course of the disease becomes necessary. The objective of this study was to describe the QoL of patients with MM in France, from their diagnosis of advanced disease to their death, in real life.
Mots clés
clinical practice, immunotherapy, metastatic melanoma, quality of life, real-life, targeted therapy
Référence
Cancer. 2019 Oct 22;: